EP1112286A1 - Proteines secretees et polynucleotides les codant - Google Patents

Proteines secretees et polynucleotides les codant

Info

Publication number
EP1112286A1
EP1112286A1 EP99942123A EP99942123A EP1112286A1 EP 1112286 A1 EP1112286 A1 EP 1112286A1 EP 99942123 A EP99942123 A EP 99942123A EP 99942123 A EP99942123 A EP 99942123A EP 1112286 A1 EP1112286 A1 EP 1112286A1
Authority
EP
European Patent Office
Prior art keywords
seq
nucleotide sequence
nucleotide
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99942123A
Other languages
German (de)
English (en)
Inventor
Kenneth Jacobs
John M. Mccoy
Edward R. Lavallie
Lisa A. Collins-Racie
Cheryl Evans
David Merberg
Maurice Treacy
Michael J. Agostino
Robert J. Ii Steininger
Vikki Spaulding
Gordon G. Wong
Hilary F. Clark
Kim Fechtel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Publication of EP1112286A1 publication Critical patent/EP1112286A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • provisional application Ser. No. 60/132,020 (GI 6082), filed April 30, 1999; (9) provisional application Ser. No. 60/XXX,XXX (GI 6083), filed August 11, 1999; all of which are incorporated by reference herein.
  • the present invention provides novel polynucleotides and proteins encoded by such polynucleotides, along with therapeutic, diagnostic and research utilities for these polynucleotides and proteins.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (n) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:l.
  • nucleotide 87 to nucleotide 821 from nucleotide 87 to nucleotide 821; the nucleotide sequence of SEQ ID NO:l from nucleotide 120 to nucleotide 821; the nucleotide sequence of SEQ ID NO:l from nucleotide 1 to nucleotide 1625; the nucleotide sequence of the full-length protein coding sequence of clone co62_12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone co62_12 deposited under accession number ATCC 98825.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone co62_12 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:l.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:l to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:l , but excluding the poly (A) tail at the 3' end of SEQ ID NO:l.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l from nucleotide 87 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 87 to nucleotide 821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 87 to nucleotide 821.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l from nucleotide 120 to nucleotide 821, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 120 to nucleotide 821, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 120 to nucleotide 821.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:l from nucleotide 1 to nucleotide 1625, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:l from nucleotide 1 to nucleotide 1625, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:l from nucleotide 1 to nucleotide 1625.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the arnino acid sequence of SEQ ID NO:2 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:2, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:2 having biological activity, the fragment comprising the amino acid sequence from amino acid 117 to amino acid 126 of SEQ ID NO:2.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:3.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:3.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone lo311_8 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:3 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:3 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:3.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 9 to nucleotide 1013.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:3 from nucleotide 96 to nucleotide 1013.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the protein comprises the amino acid sequence of SEQ ID NO:4.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:4, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:4 having biological activity, the fragment comprising the amino acid sequence from amino acid 162 to amino acid 171 of SEQ ID NO:4.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:5.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone nsl97_l deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:5 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:5 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:5.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of
  • SEQ ID NO:5 from nucleotide 352 to nucleotide 825, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:5 from nucleotide 352 to nucleotide 825.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the protein comprises the amino acid sequence of SEQ ID NO:6.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:6, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:6 having biological activity, the fragment comprising the amino acid sequence from amino acid 74 to amino acid 83 of SEQ ID NO:6.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:8;
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:7.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pjl93_5 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:7 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:7 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:7.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 86 to nucleotide 829.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:7 from nucleotide 149 to nucleotide 829.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:8, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:8 having biological activity, the fragment comprising the amino acid sequence from amino acid 119 to amino acid 128 of SEQ ID NO:8.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:9.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pj317_2 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:10, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:9 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:9 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:9.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:9 from nucleotide 174 to nucleotide 1292.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:10, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:10 having biological activity, the fragment comprising the amino acid sequence from amino acid 181 to amino acid 190 of SEQ ID NO:10.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone pt332_l deposited under accession number ATCC 98825;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:ll from nucleotide 7 to nucleotide 2517; the nucleotide sequence of SEQ ID NO:ll from nucleotide 904 to nucleotide 2517; the nucleotide sequence of the full-length protein coding sequence of clone pt332_l deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone pt332_l deposited under accession number ATCC 98825.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pt332_l deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:12, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:ll. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:ll, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 11 from nucleotide 7 to nucleotide 2517, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO: 11 from nucleotide 7 to nucleotide 2517, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 7 to nucleotide 2517.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:ll from nucleotide 904 to nucleotide 2517, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:ll from nucleotide 904 to nucleotide 2517, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO: 11 from nucleotide 904 to nucleotide 2517.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 12, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 12 having biological activity, the fragment comprising the amino acid sequence from amino acid 413 to amino acid 422 of SEQ ID NO:12.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 13 from nucleotide 18 to nucleotide 257; the nucleotide sequence of the full-length protein coding sequence of clone qc297_15 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qc297_15 deposited under accession number ATCC 98825.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qc297_15 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO: 14, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment comprising the a ino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO.14.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:13.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:13 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:13 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:13.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:13 from nucleotide 18 to nucleotide 257.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the protein comprises the amino acid sequence of SEQ ID NO:14.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:14 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:14, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 14 having biological activity, the fragment comprising the amino acid sequence from amino acid 35 to amino acid 44 of SEQ ID NO:14.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432; the nucleotide sequence of the full-length protein coding sequence of clone qg596_12 deposited under accession number ATCC 98825; or the nucleotide sequence of a mature protein coding sequence of clone qg596_12 deposited under accession number ATCC 98825.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done qg596_12 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:16, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:15.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:15 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:15 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:15.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 15 from nucleotide 21 to nucleotide 2432, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:15 from nucleotide 21 to nucleotide 2432.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO: 16 the fragment comprising eight contiguous amino acids of SEQ ID NO: 16; and (c) the amino acid sequence encoded by the cDNA insert of clone qg596_12 deposited under accession number ATCC 98825; the protein being substantially free from other mammalian proteins.
  • the protein comprises the arnino acid sequence of SEQ ID NO: 16.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 16, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 16 having biological activity, the fragment comprising the amino acid sequence from amino acid 397 to amino acid 406 of SEQ ID NO:16.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:17.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:17.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rb649_3 deposited under accession number ATCC 98825.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:18, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO: 18 having biological activity, the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:17 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:17 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:17.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 17 from nucleotide 339 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 339 to nucleotide 2105.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:17 from nucleotide 501 to nucleotide 2105.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:18;
  • the protein comprises the amino acid sequence of SEQ ID NO:18.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:18 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO: 18, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 289 to amino acid 298 of SEQ ID NO:18.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:19;
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:20;
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:19.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467; the nucleotide sequence of the full-length protein coding sequence of clone cal06_19x deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone cal06_19x deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cal06_19x deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:20, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.
  • step (bb) the nucleotide sequence of the cDNA insert of clone cal06_19x deposited under accession number ATCC 98835; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 19, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:19 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:19 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:19.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:19 from nucleotide 509 to nucleotide 2467.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:20, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:20 having biological activity, the fragment comprising the amino acid sequence from amino acid 321 to amino acid 330 of SEQ ID NO:20.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:21;
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone ci52_2 deposited under accession number ATCC 98835;
  • (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:21.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802; the nucleotide sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802; the nucleotide sequence of the full-length protein coding sequence of clone ci52_2 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone d52_2 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ci52_2 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:21 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:21 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:21.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 179 to nucleotide 802.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:21 from nucleotide 242 to nudeotide 802, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:21 from nucleotide 242 to nucleotide 802.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:22, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:22 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:22.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714; the nucleotide sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714; the nucleotide sequence of the full-length protein coding sequence of clone mdl24_16 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone mdl24_16 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone mdl24_16 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:24, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone mdl24_16 deposited under accession number ATCC 98835; ( ⁇ ) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:23 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:23 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:23.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 46 to nucleotide 714.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:23 from nucleotide 538 to nudeotide 714, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:23 from nucleotide 538 to nucleotide 714.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:24, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:24 having biological activity, the fragment comprising the amino acid sequence from amino acid 106 to amino acid 115 of SEQ ID NO:24.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726; the nucleotide sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726; the nucleotide sequence of the full-length protein coding sequence of clone pk366_7 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pk366_7 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done pk366_7 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:26, or a polynucleotide encoding a protein comprising a fragment of the arnino acid sequence of SEQ ID NO:26 having biological activity, the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ IDNO:25.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:25 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:25 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:25.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 92 to nucleotide 1726.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:25 from nucleotide 1211 to nucleotide 1726.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:26;
  • the protein comprises the amino acid sequence of SEQ ID NO:26.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:26 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:26, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 267 to amino acid 276 of SEQ ID NO:26.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788; the nucleotide sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788; the nucleotide sequence of the full-length protein coding sequence of clone pl741_5 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pl741_5 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pl741_5 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:28, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:27.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:27 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:27 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:27.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 16 to nucleotide 1788.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:27 from nucleotide 61 to nucleotide 1788.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:28 (b) a fragment of the amino acid sequence of SEQ ID NO:28, the fragment comprising eight contiguous amino acids of SEQ ID NO:28; and (c) the amino acid sequence encoded by the cDNA insert of clone pl741_5 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:28.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:28, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:28 having biological activity, the fragment comprising the amino acid sequence from amino acid 290 to amino acid 299 of SEQ ID NO:28.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338; the nucleotide sequence of the full-length protein coding sequence of clone pp314_19 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone pp314_19 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pp314_19 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:30, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.
  • step (ba) SEQ ID NO:29, but excluding the poly(A) tail at the 3' end of SEQ ID NO:29; and (bb) the nucleotide sequence of the cDNA insert of clone pp314_19 deposited under accession number ATCC 98835; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:29 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:29 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:29.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:29 from nucleotide 629 to nucleotide 2338.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of :
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:30, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:30 having biological activity, the fragment comprising the amino acid sequence from amino acid 280 to amino acid 289 of SEQ ID NO:30.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:31.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:31
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv35_l deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:32, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • step (bb) the nucleotide sequence of the cDNA insert of clone pv35_l deposited under accession number ATCC 98835; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:31 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:31 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:31.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:31 from nucleotide 158 to nucleotide 1102.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:32;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:32, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:32 having biological activity, the fragment comprising the amino acid sequence from amino acid 152 to amino acid 161 of SEQ ID NO:32.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:33.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:33
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of done pw337_6 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:34, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • step (bb) the nucleotide sequence of the cDNA insert of clone pw337_6 deposited under accession number ATCC 98835; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:33 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:33 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:33.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:33 from nucleotide 413 to nucleotide 733.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:34;
  • the protein comprises the amino acid sequence of SEQ ID NO:34.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:34 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:34, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 48 to amino acid 57 of SEQ ID NO:34.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:35.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:35
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd610_l deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • step (bb) the nucleotide sequence of the cDNA insert of clone rd610_l deposited under accession number ATCC 98835; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:35 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:35 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:35.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:35 from nucleotide 678 to nucleotide 938.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:36;
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:36, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:36 having biological activity, the fragment comprising the amino acid sequence from amino acid 38 to amino acid 47 of SEQ ID NO:36.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494; the nucleotide sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494; the nucleotide sequence of the full-length protein coding sequence of clone rd810_6 deposited under accession number ATCC 98835; or the nucleotide sequence of a mature protein coding sequence of clone rd810_6 deposited under accession number ATCC 98835.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd810_6 deposited under accession number ATCC 98835.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:38, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ IDNO:37.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:37 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:37 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:37.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 75 to nucleotide 494.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:37 from nucleotide 447 to nucleotide 494.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:38 (b) a fragment of the amino acid sequence of SEQ ID NO:38, the fragment comprising eight contiguous amino acids of SEQ ID NO:38; and (c) the amino acid sequence encoded by the cDNA insert of clone rd810_6 deposited under accession number ATCC 98835; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:38.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:38, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:38 having biological activity, the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:38.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone cf85_l deposited under accession number ATCC 98850;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:39.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080; the nucleotide sequence of the full-length protein coding sequence of clone cf85_l deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone cf85_l deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone cf85_l deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:39 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:39 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:39.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:39 from nucleotide 181 to nucleotide 1080.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:40, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:40 having biological activity, the fragment comprising the amino acid sequence from amino acid 145 to amino acid 154 of SEQ ID NO:40.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348; the nucleotide sequence of SEQ ID NO:41 from nucleotide 599 to nucleotide 1348; the nucleotide sequence of the full-length protein coding sequence of clone dd504_18 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone dd504_18 deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone dd504_18 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:42, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.
  • step (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide
  • nucleotide 1348 and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:41 from nucleotide 161 to nucleotide 1348, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:41 from nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO: 1
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:42 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:42, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:42 having biological activity, the fragment comprising the amino acid sequence from amino acid 193 to amino acid 202 of SEQ ID NO:42.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:43.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386; the nucleotide sequence of the full-length protein coding sequence of clone np26_3 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone np26_3 deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone np26_3 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:44, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino add sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:43.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:43 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:43 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:43.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:43 from nucleotide 70 to nucleotide 1386.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:44 (b) a fragment of the amino acid sequence of SEQ ID NO:44, the fragment comprising eight contiguous amino acids of SEQ ID NO:44; and (c) the amino acid sequence encoded by the cDNA insert of clone np26_3 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins.
  • such protein comprises the amino acid sequence of SEQ ID NO:44.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:44, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:44 having biological activity, the fragment comprising the amino acid sequence from amino acid 214 to amino acid 223 of SEQ ID NO:44.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:45.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515; the nucleotide sequence of the full-length protein coding sequence of clone pm412_12 deposited under accession number ATCC
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm412__12 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:46, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino add sequence from amino add 571 to amino acid 580 of SEQ ID NO:46.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:45.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:45 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:45 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:45.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:45 from nucleotide 60 to nucleotide 3515.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:46 (b) a fragment of the amino acid sequence of SEQ ID NO:46, the fragment comprising eight contiguous amino acids of SEQ ID NO:46; and (c) the amino acid sequence encoded by the cDNA insert of clone pm412_12 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins.
  • such protein comprises the amino acid sequence of SEQ ID NO:46.
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:46 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:46, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:46 having biological activity, the fragment comprising the amino acid sequence from amino acid 571 to amino acid 580 of SEQ ID NO:46.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780; the nucleotide sequence of SEQ ID NO:47 from nucleotide 1556 to nucleotide 1780; the nucleotide sequence of the full-length protein coding sequence of clone pm421_3 deposited under accession number ATCC
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pm421_3 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:48, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • step (bb) the nucleotide sequence of the cDNA insert of clone pm421_3 deposited under accession number ATCC 98850; (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:47 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:47 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:47.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:47 from nucleotide 1490 to nucleotide 1780.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino add sequence of SEQ ID NO:48 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:48, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:48 having biological activity, the fragment comprising the amino acid sequence from amino acid 43 to amino acid 52 of SEQ ID NO:48.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486; the nucleotide sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486; the nucleotide sequence of the full-length protein coding sequence of clone pv6_l deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone pv6_l deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pv6_l deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:50, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment comprising the amino add sequence from amino acid 65 to amino add 74 of SEQ ID NO:50.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:49.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • step (ii) hybridizing said primer(s) to human genomic DNA in conditions at least as stringent as 4X SSC at 50 degrees C; (iii) amplifying human DNA sequences; and (iv) isolating the polynucleotide products of step (b)(iii).
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:49 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:49 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:49.
  • the polynudeotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 64 to nucleotide 486.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:49 from nucleotide 217 to nucleotide 486.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:50;
  • the protein comprises the amino acid sequence of SEQ ID NO:50.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:50 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:50, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 65 to amino acid 74 of SEQ ID NO:50.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(j) and that has a length that is at least 25% of the length of SEQ ID NO:51.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:51
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qsl4_3 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:52, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 379 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:
  • nucleotide 460 to nucleotide 3783 and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 460 to nucleotide 3783.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:51 from nucleotide 1983 to nucleotide 3938.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:52;
  • a fragment of the amino acid sequence of SEQ ID NO:52 (c) a fragment of the amino acid sequence of SEQ ID NO:52, the fragment comprising eight contiguous amino acids of SEQ ID NO:52; and (d) the amino acid sequence encoded by the cDNA insert of clone qsl4_3 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins.
  • such protein comprises the amino acid sequence of SEQ ID NO:52 or the amino acid sequence of SEQ ID NO:52 from amino acid 536 to amino acid 1135.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:52, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:52 having biological activity, the fragment comprising the amino acid sequence from amino acid 562 to amino acid 571 of SEQ ID NO:52.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising eight contiguous amino acids of SEQ ID NO:54;
  • (k) a polynudeotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:53.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qy338_9 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:54, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.
  • Other embodiments provide the gene corresponding to the cDNA sequence of SEQ
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of: (i) preparing one or more polynucleotide probes that hybridize in 6X SSC at 65 degrees C to a nucleotide sequence selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53 from nucleotide 1 to nucleotide
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:53
  • nucleotide 469 to nucleotide 843 from nucleotide 469 to nucleotide 843, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:53 from nucleotide 469 to nucleotide 843.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:54, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:54 having biological activity, the fragment comprising the amino acid sequence from amino acid 135 to amino acid 144 of SEQ ID NO:54.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone rc58_l deposited under accession number ATCC 98850;
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906; the nucleotide sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906; the nucleotide sequence of the full-length protein coding sequence of clone rc58_l deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rc58_l deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rc58_l deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the arnino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:56, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:55. Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 283 to nucleotide 906.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:55 from nucleotide 325 to nucleotide 906.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:56, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:56 having biological activity, the fragment comprising the amino acid sequence from amino acid 99 to amino acid 108 of SEQ ID NO:56.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973; the nucleotide sequence of the full-length protein coding sequence of clone rd232_5 deposited under accession number ATCC 98850; or the nucleotide sequence of a mature protein coding sequence of clone rd232_5 deposited under accession number ATCC 98850.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd232_5 deposited under accession number ATCC 98850.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino add sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:57.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:57 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:57 , but excluding the ⁇ oly(A) tail at the 3' end of SEQ ID NO:57.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:57 from nucleotide 56 to nucleotide 973.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:58 (b) a fragment of the amino acid sequence of SEQ ID NO:58, the fragment comprising eight contiguous amino acids of SEQ ID NO:58; and (c) the amino acid sequence encoded by the cDNA insert of clone rd232_5 deposited under accession number ATCC 98850; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:58.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:58, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:58 having biological activity, the fragment comprising the amino acid sequence from amino acid 148 to amino acid 157 of SEQ ID NO:58.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596; the nucleotide sequence of the full-length protein coding sequence of clone ck213_12 deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone ck213_12 deposited under accession number ATCC 98918.
  • the polynudeotide encodes the full-length or a mature protein encoded by the cDNA insert of clone ck213_12 deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:60, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:59.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:59 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:59 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:59.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:59 from nucleotide 893 to nucleotide 2596.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino add sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:60 (b) a fragment of the amino acid sequence of SEQ ID NO:60, the fragment comprising eight contiguous amino acids of SEQ ID NO:60; and (c) the amino acid sequence encoded by the cDNA insert of clone ck213_12 deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins.
  • a fragment of the amino acid sequence of SEQ ID NO:60 the fragment comprising eight contiguous amino acids of SEQ ID NO:60
  • the amino acid sequence encoded by the cDNA insert of clone ck213_12 deposited under accession number ATCC 98918 the protein being substantially free from other mammalian proteins.
  • such protein comprises the amino acid sequence of SEQ ID NO:60.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:60, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:60 having biological activity, the fragment comprising the amino acid sequence from amino acid 279 to amino acid 288 of SEQ ID NO:60.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750; the nucleotide sequence of the full-length protein coding sequence of clone pgl95_l deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone pgl95_l deposited under accession number ATCC 98918.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pgl95_l deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino add sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.
  • inventions provide the gene corresponding to the cDNA sequence of SEQ ID NO:61.
  • Further embodiments of the invention provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:61 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:61 , but excluding the poly (A) tail at the 3' end of SEQ ID NO:61.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:61 from nucleotide 29 to nucleotide 1750.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • a fragment of the amino acid sequence of SEQ ID NO:62 (b) a fragment of the amino acid sequence of SEQ ID NO:62, the fragment comprising eight contiguous amino acids of SEQ ID NO:62; and (c) the amino acid sequence encoded by the cDNA insert of clone pgl95_l deposited under accession number ATCC 98918; the protein being substantially free from other mammalian proteins.
  • the protein comprises the amino acid sequence of SEQ ID NO:62.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:62, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:62 having biological activity, the fragment comprising the amino acid sequence from amino acid 282 to amino acid 291 of SEQ ID NO:62.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:63.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:63
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone pw460_5 deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:63 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:63 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:63.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1147 to nudeotide 1440, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 1147 to nucleotide 1440.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, and extending contiguously from a nudeotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:63 from nucleotide 1234 to nucleotide 1440.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of SEQ ID NO:64;
  • the protein comprises the amino acid sequence of SEQ ID NO:64.
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:64 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:64, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 44 to amino acid 53 of SEQ ID NO:64.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO:65;
  • a polynucleotide comprising the nucleotide sequence of a mature protein coding sequence of clone qal36_l deposited under accession number ATCC 98918;
  • (m) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:65.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356; the nucleotide sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356; the nucleotide sequence of the full-length protein coding sequence of clone qal36_l deposited under accession number ATCC 98918; or the nucleotide sequence of a mature protein coding sequence of clone qal36_l deposited under accession number ATCC 98918.
  • the polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qal36_l deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino add 213 to amino acid 222 of SEQ ID NO:66.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 46 to nucleotide 1356, to a nucleotide sequence corresponding to the 3' end of said sequence of
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:65 from nucleotide 127 to nucleotide 1356.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:66, or a protein comprising a fragment of the amino acid sequence of SEQ ID NO:66 having biological activity, the fragment comprising the amino acid sequence from amino acid 213 to amino acid 222 of SEQ ID NO:66.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID NO: (a) a polynucleotide comprising the nucleotide sequence of SEQ ID
  • (k) a polynucleotide which encodes a species homologue of the protein of (h) or (i) above ; (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i); and
  • polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(i) and that has a length that is at least 25% of the length of SEQ ID NO:67.
  • polynucleotide comprises the nucleotide sequence of SEQ ID NO:67.
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone qyl261_2 deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:68, or a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment comprising the amino acid sequence from amino add 231 to amino acid 240 of SEQ ID NO:68.
  • inventions provide isolated polynucleotides produced according to a process selected from the group consisting of: (a) a process comprising the steps of:
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67, and extending contiguously from a nucleotide sequence corresponding to the 5' end of SEQ ID NO:67 to a nucleotide sequence corresponding to the 3' end of SEQ ID NO:67 , but excluding the poly(A) tail at the 3' end of SEQ ID NO:67.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 206 to nucleotide 1624.
  • the polynucleotide isolated according to the above process comprises a nucleotide sequence corresponding to the cDNA sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, and extending contiguously from a nucleotide sequence corresponding to the 5' end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624, to a nucleotide sequence corresponding to the 3' end of said sequence of SEQ ID NO:67 from nucleotide 542 to nucleotide 1624.
  • the present invention provides a composition comprising a protein, wherein said protein comprises an amino acid sequence selected from the group consisting of:
  • the present invention provides a protein comprising a fragment of the amino acid sequence of SEQ ID NO:68 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino adds of SEQ ID NO:68, or a protein comprising a fragment of the amino acid sequence of SEQ
  • the fragment comprising the amino acid sequence from amino acid 231 to amino acid 240 of SEQ ID NO:68.
  • the present invention provides a composition comprising an isolated polynucleotide selected from the group consisting of:
  • a polynucleotide which is an allelic variant of a polynucleotide of (a)-(f) above (j) a polynucleotide which encodes a species homologue of the protein of (g) or (h) above ;
  • (k) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h); and (1) a polynucleotide that hybridizes under stringent conditions to any one of the polynucleotides specified in (a)-(h) and that has a length that is at least 25% of the length of SEQ ID NO:69.
  • such polynucleotide comprises the nucleotide sequence of SEQ ID NO: 1
  • polynucleotide encodes the full-length or a mature protein encoded by the cDNA insert of clone rd432_4 deposited under accession number ATCC 98918.
  • the present invention provides a polynucleotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment preferably comprising eight (more preferably twenty, most preferably thirty) contiguous amino acids of SEQ ID NO:70, or a polynudeotide encoding a protein comprising a fragment of the amino acid sequence of SEQ ID NO:70 having biological activity, the fragment comprising the amino acid sequence from amino acid 71 to amino acid 80 of SEQ ID NO:70.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention concerne des polynucléotides nouvellement découverts ainsi que des protéines codées par de tels polynucléotides.
EP99942123A 1998-08-14 1999-08-13 Proteines secretees et polynucleotides les codant Withdrawn EP1112286A1 (fr)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US9662298P 1998-08-14 1998-08-14
US96622P 1998-08-14
US9681598P 1998-08-17 1998-08-17
US96815P 1998-08-17
US9922998P 1998-09-04 1998-09-04
US99229P 1998-09-04
US10536898P 1998-10-23 1998-10-23
US105368P 1998-10-23
US11523499P 1999-01-08 1999-01-08
US115234P 1999-01-08
US11993199P 1999-02-12 1999-02-12
US119931P 1999-02-12
US12057599P 1999-02-18 1999-02-18
US120575P 1999-02-18
US13202099P 1999-04-30 1999-04-30
US132020P 1999-04-30
US14842499P 1999-08-11 1999-08-11
US148424P 1999-08-11
PCT/US1999/018298 WO2000009552A1 (fr) 1998-08-14 1999-08-13 Proteines secretees et polynucleotides les codant

Publications (1)

Publication Number Publication Date
EP1112286A1 true EP1112286A1 (fr) 2001-07-04

Family

ID=27578412

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99942123A Withdrawn EP1112286A1 (fr) 1998-08-14 1999-08-13 Proteines secretees et polynucleotides les codant

Country Status (4)

Country Link
EP (1) EP1112286A1 (fr)
JP (1) JP2002522062A (fr)
CA (1) CA2339047A1 (fr)
WO (1) WO2000009552A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE474849T1 (de) 1998-04-14 2010-08-15 Chugai Pharmaceutical Co Ltd Neues cytokinartiges protein
US20030009013A1 (en) * 1998-12-30 2003-01-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7034132B2 (en) 2001-06-04 2006-04-25 Anderson David W Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2000078802A2 (fr) * 1999-06-23 2000-12-28 Curagen Corporation Polypeptides secretes et polynucleotides correspondants
AU7680300A (en) * 1999-08-18 2001-03-13 Fraunhofer-Gesellschaft Zur Forderung Der Angewandten Forschung E.V. Human dna sequences
CA2376361A1 (fr) * 1999-08-19 2001-03-01 Genset S.A. Gene 3 lie au cancer de la prostate (pg-3) et marqueurs bialleliques
AU7728100A (en) * 1999-09-28 2001-04-30 Zymogenetics Inc. Membrane-bound protein-60
FR2801056B1 (fr) * 1999-11-12 2003-03-28 Commissariat Energie Atomique Proteine presente a la surface des cellules souches hematopoietiques de la lignee lymphoide et des cellules nk, et ses applications
WO2001087917A1 (fr) * 2000-05-18 2001-11-22 Hyseq, Inc. Nouveaux acides nucleiques et polypeptides
WO2002010196A2 (fr) * 2000-07-28 2002-02-07 Merck Patent Gmbh Identification d'un nouveau transporteur de glutamine
WO2002016599A2 (fr) * 2000-08-25 2002-02-28 Curagen Corporation Nouvelles proteines et acides nucleiques les codant
WO2002062945A2 (fr) 2000-10-25 2002-08-15 Diadexus, Inc. Compositions et techniques relatives a des genes et a des proteines specifiques du poumon
US7608704B2 (en) 2000-11-08 2009-10-27 Incyte Corporation Secreted proteins
EP1341812A2 (fr) * 2000-11-08 2003-09-10 Incyte Genomics, Inc. Proteines secretees
AU2002245158A1 (en) * 2000-12-18 2002-07-30 Millennium Pharmaceuticals, Inc. Human proteins 55562 and 21617, and methods of use thereof
JP2004520055A (ja) * 2001-02-20 2004-07-08 ジェンセット Ｐｇ−３およびｐｇ−３の二対立遺伝子マーカー
EP1623011B1 (fr) 2003-05-09 2013-01-02 Janssen Biotech, Inc. Proteines derivees de l'immunoglobine specifiques de il-23p40, compositions, procedes et utilisations
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
CA2613818C (fr) 2005-06-30 2013-08-27 Centocor, Inc. Anticorps anti-il-23, compositions, methodes et utilisations
CA2618047C (fr) * 2005-08-05 2015-04-14 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Nouveau peptide intervenant dans l'homeostasie energetique
SI3219328T1 (sl) 2005-12-29 2020-10-30 Janssen Biotech, Inc. Človeška protitelesa proti-IL-23, sestavki, postopki in uporabe
MA55149A (fr) 2018-11-20 2021-09-29 Janssen Biotech Inc Procédé sûr et efficace de traitement du psoriasis avec un anticorps spécifique anti-il-23
EP3972690A4 (fr) 2019-05-23 2023-07-05 Janssen Biotech, Inc. Méthode de traitement de maladie intestinale inflammatoire au moyen d'une polythérapie d'anticorps dirigés contre il -23 et tnf alpha
CA3183927A1 (fr) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Methode de traitement d'une maladie intestinale inflammatoire au moyen d'une polytherapie d'anticorps diriges contre il-23 et tnf alpha

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6891098A (en) * 1997-04-10 1998-10-30 Genetics Institute Inc. Secreted expressed sequence tags (sests)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0009552A1 *

Also Published As

Publication number Publication date
WO2000009552A1 (fr) 2000-02-24
WO2000009552A9 (fr) 2002-02-14
CA2339047A1 (fr) 2000-02-24
JP2002522062A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
WO2000055375A1 (fr) Proteines secretees et polynucleotides les codant
WO2000009552A1 (fr) Proteines secretees et polynucleotides les codant
US20080139452A1 (en) Secreted proteins and polynucleotides encoding them
EP1056764A1 (fr) Proteines secretees et polynucleotides codant lesdites proteines
EP1068307A1 (fr) Proteines secretees et polynucleotides les codant
WO1999046287A1 (fr) Proteines secretees et polynucleotides les codant
EP1053252A1 (fr) Proteines secretees et polynucleotides les codant
EP1040118A1 (fr) Proteines secretees et polynucleotides les codant
WO2000050592A1 (fr) Proteines secretees et polynucleotides les codant
EP1070124A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
WO1999035252A2 (fr) Proteines secretees et polynucleotides les codant
WO1999026973A1 (fr) Proteines secretees et polynucleotides les codant
EP1068308A1 (fr) Proteines secretees et polynucleotides codant pour ces proteines
WO1999037674A1 (fr) Proteines secretees et polynucleotides les codant
WO1999047555A1 (fr) Proteines secretees et polynucleotides les codant
EP1051481A1 (fr) Proteines secretees et polynucleotides codant pour elles
WO2001075133A1 (fr) Proteines secretees et polynucleotides codant pour celles-ci
EP1028974A1 (fr) Proteines secretees et polynucleotides les codant
EP1012263A1 (fr) Proteines secretees et polynucleotides les codant
WO1999035165A1 (fr) Proteines secretees et polynucleotides les codant
WO1999036512A1 (fr) Proteines secretees et polynucleotides les codant
EP1177440A1 (fr) Proteines secretees et polynucleotides codant ces dernieres
WO2000066148A1 (fr) Nouvelles proteines
WO2001075074A1 (fr) Nouvelles proteines
EP1036087A1 (fr) Proteines secretees et polynucleotides les codant

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010314

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AGOSTINO, MICHAEL, J.

Inventor name: TREACY, MAURICE

Inventor name: MERBERG, DAVID

Inventor name: EVANS, CHERYL

Inventor name: COLLINS-RACIE, LISA, A.

Inventor name: LAVALLIE, EDWARD, R.

Inventor name: MCCOY, JOHN, M.

Inventor name: JACOBS, KENNETH

RIN1 Information on inventor provided before grant (corrected)

Inventor name: AGOSTINO, MICHAEL, J.

Inventor name: TREACY, MAURICE

Inventor name: MERBERG, DAVID

Inventor name: EVANS, CHERYL

Inventor name: COLLINS-RACIE, LISA, A.

Inventor name: LAVALLIE, EDWARD, R.

Inventor name: MCCOY, JOHN, M.

Inventor name: JACOBS, KENNETH

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GENETICS INSTITUTE, LLC

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20030521